Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

By I. McInnes, P. Mease, B. Kirkham, A. Kavanaugh, C. Ritchlin, P. Rahman, D. van der Heijde, R. Landewé, Philip G. Conaghan, A. Gottlieb and 5 more. The Lancet, 2015

770 citations recorded by the source corpus.

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/7d18d5123050431857c4ff6fceb8f03241d524ba

Citations in the corpus

• Immunopathogenesis of rheumatoid arthritis (2017, neutral): “…including IL-17A and IL-17RA inhibitors have as yet not been particularly effective in established RA trials despite remarkable responses being 190 Immunity 46, February 21, 2017 achieved in psoriasis (Langley et al., 2014) and to some extent spondyloarthropathies (McInnes et al., 2015).”